
|Articles|December 4, 2007
Open letter from Genentech
Click here to read Genentech's open letter to ophthalmologists, outlining its reason for imposing restrictions on the use of Avastin.
Advertisement
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times Europe
1
FLORetina 2025: Navigating antithrombotic therapy in wet AMD
2
FLORetina 2025: Port delivery system shows reliable 6-month durability and sustained efficacy in neovascular AMD for up to 7 years
3
FLORetina 2025: Multimodal deep learning for CKD diagnosis using retinal images and urine dipstick data
4
FLORetina 2025: Rethinking Terson syndrome through multimodal imaging
5













































